Latest News and Press Releases
Want to stay updated on the latest news?
-
Data published in Neuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva,...
-
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 15, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
-
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 1, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
-
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 18, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
-
ADX71149 Phase 2 epilepsy clinical study’s independent interim review committee (“IRC”) recommends continuing study CHF 5.6M ($ 6.1M) of cash and cash equivalents at March 31, 2023 Ad Hoc...
-
Cohort 1 progressing through Part 2Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a...
-
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
-
Geneva, Switzerland, May 4, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
-
Proceeds to advance allosteric modulator therapeutic pipeline Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 5, 2023 – Addex Therapeutics Ltd (SIX: ADXN and...
-
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 4, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...